



Contact: Tim Pelura, CEO, (484) 476-1396, tjelura@immunomeinc.com

Immunome Completes Financing to Advance Infectious Disease Drug Discovery

Wynnewood, PA – May 24, 2010 - Immunome, a discovery-stage antibody platform company focused on life-threatening infectious diseases, announced today the completion of a financing by BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania. The funding round also included private investors.

“This financing will enable Immunome to identify our first therapeutic candidate for serious infectious diseases utilizing our unparalleled monoclonal antibody technology,” said Tim Pelura, president and CEO of Immunome. “Immunome’s technology, licensed from MIT and Thomas Jefferson University, enables us to harness the natural curative potential of the human immune system. Based on preliminary work, we believe that the novel antibodies generated by this technology could have unique properties that may provide significant clinical benefit. Immunome is harnessing this technology to develop novel therapies for infections which currently have no or few treatment options.”

Infectious diseases remain the third leading cause of death in the United States each year and the second ranking cause of death worldwide according to The World Health Organization. The use of broad-spectrum antibiotics has resulted in the emergence of micro-organisms resistant to multiple therapies (superbugs) and physicians are seeing an increasing number of patients with life threatening infections for which they have limited treatment options.

“The ability to access native human antibodies has been hampered by the lack of a suitable fusion partner and other technical challenges,” said Barbara S. Schilberg, managing director and CEO, BioAdvance. “Immunome’s technology addresses these challenges and allows capital-efficient identification of antibodies engineered by the human body itself. We look forward to working with this accomplished team to demonstrate the potential of this technology.”

About Immunome

Immunome is a discovery stage biopharmaceutical company that has created a proprietary Native Human Monoclonal Antibody (N-huMAB) platform. N-huMAbs are in the exact structures created by nature and possess the natural safety and protective power of the human immune system. The Immunome method is an optimized hybridoma method that exclusively

produces affinity-matured IgG N-huMAbs. The method begins with small blood samples obtained from volunteer donors who are immune to pathogens of interest. B-cells from these donors are converted to stable hybridoma cells that express full-length N-huMAbs that are specific for those pathogens. The strength of the Immunome technology is its ability to capture the innate immune response to infectious diseases and for vaccines. The Immunome method is intrinsically unbiased, so Immunome is able to obtain N-huMAbs not accessible by other antibody cloning methods. Because the Immunome hybridomas express N-huMAbs in their authentic, full-length configurations, Immunome's N-huMAbs are suitable for functional testing without modification. Immunome has captured high affinity, potent N-huMAbs in several therapeutic classes – infectious disease, neurological illness, and biodefense. Immunome has focused its internal development efforts on life-threatening infectious diseases.

www.immunomeinc.com